SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

BPTH RSS Feed
Add BPTH Price Alert      Hide Sticky   Hide Intro
Moderator: SJSTOCKSHARK
Search This Board:
Last Post: 9/29/2016 3:38:34 PM - Followers: 36 - Board type: Free - Posts Today: 0
Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with Ara-C) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug to begin phase II. The patient dosing has begun at MD Anderson, Baylor and University of Kansas.


Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the 8 cohort of phase 1 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. With the completion of the combination safety trials with Ara-C and FDA approval, phase 2 has begun and is accepting patients.  This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore an FDA accelerated status after testing is complete on 19 additional patients.
 
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. 

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability o
f its pipeline to modulate pancreatic cancer.


http://www.biopathholdings.com


While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest.  Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional 10 million dollars the company has $13+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

 
Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
 
BPTH is traded on the NASDAQ.

Here is the link to the recent peer paper prepared by their experts:

http://www.biopathholdings.com/pdf/PeerExpertOpinion20150107.pdf

Analyst target price: Maxim $2, Zacks $3.50 and Rodman & Renshaw $5
                        
 
 
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BPTH
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#2205   I do not think that the weak PPS Gpheart2013 09/29/16 03:38:33 PM
#2204   I am guessing that testing isn't going very vrock5656 09/29/16 01:34:00 PM
#2203   Not a very good signal ... just tanking vrock5656 09/26/16 11:34:01 AM
#2202   A buyout would be perfect. That could happen wordlender 09/23/16 05:33:52 PM
#2201   I am ready for a buyout. Check out SJSTOCKSHARK 09/21/16 03:07:51 PM
#2200   Still 13% of total shares owned by institutional investment. SJSTOCKSHARK 09/19/16 04:30:35 PM
#2199   Wordl. I wonder if those purchases related the SJSTOCKSHARK 09/19/16 01:54:27 PM
#2198   Thank you love. Gpheart2013 09/16/16 07:39:20 PM
#2197   It is because I sold all of mine iloveu2 09/16/16 01:51:03 PM
#2196   What is going on this morning? A big Gpheart2013 09/16/16 10:10:00 AM
#2195   With Biopath being in phase 2 efficacy trial wingshooterr 09/15/16 10:43:36 PM
#2194   Did you guys see this article? wordlender 09/15/16 04:03:55 PM
#2193   Nah I don't think it is going to Teeds 09/15/16 01:40:15 PM
#2192   This is going under $1.00 iloveu2 09/15/16 09:56:15 AM
#2191   You guys must be right sorry for the error. SJSTOCKSHARK 09/15/16 12:24:45 AM
#2190   I'm out, all sold, good luck to you iloveu2 09/14/16 02:14:19 PM
#2189   You are correct! 4th is coming soon BPTH2008 09/14/16 12:22:01 PM
#2188   It's not moving at a snails pace it's vrock5656 09/14/16 10:56:50 AM
#2187   Three study sites are listed for the phase Gpheart2013 09/14/16 10:51:38 AM
#2186   SJ, I thought he was taking about study Brettj 09/14/16 10:28:45 AM
#2185   I believe he said 3 sites and a BPTH2008 09/14/16 09:23:25 AM
#2184   I wish I could understand why this is too simple 09/14/16 09:20:10 AM
#2183   Brettj, PN said 3 enrolled in stage II SJSTOCKSHARK 09/13/16 11:09:47 PM
#2182   Well, I am out, having more fun and iloveu2 09/13/16 10:29:00 PM
#2181   He had updated slides. Some new graphs showing Brettj 09/13/16 08:42:32 PM
#2180   Does anyone see anything new in today's presentation? blairsoldman 09/13/16 07:18:16 PM
#2179   ^^^^This^^^ tyroneweaver 09/13/16 11:15:16 AM
#2178   Love it, first time I have smiled about iloveu2 09/12/16 09:45:13 PM
#2177   iloveu2 I can't respond any better than this: SJSTOCKSHARK 09/12/16 08:27:53 PM
#2176   Is tomorrow just the same old, same old iloveu2 09/12/16 07:30:30 PM
#2175   I vaguely remember Tyrone posting something about this. Pat Torney 09/12/16 01:35:06 PM
#2174   Is $1.40 a buying opportunity? I'm not sure. Gpheart2013 09/10/16 11:51:38 AM
#2173   Ty, Would you refresh the Board with the SJSTOCKSHARK 09/10/16 10:36:10 AM
#2172   Remember When I mentioned Wasatch Front scams? tyroneweaver 09/10/16 12:29:05 AM
#2171   BrettJ, Zack's still has BioPath listed as a Snug9 09/07/16 11:02:11 PM
#2170   $2.00 target price in updated Maxim rating! PN Brettj 09/07/16 05:35:23 PM
#2169   HOUSTON, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Bio-Path SJSTOCKSHARK 09/06/16 11:25:58 AM
#2168   I wonder why no PR happened with this news? SJSTOCKSHARK 09/02/16 11:29:22 AM
#2167   A third cancer center is listed for the Gpheart2013 09/02/16 10:44:05 AM
#2166   Next support level is $1.54. It looks to Gpheart2013 08/26/16 07:53:25 PM
#2165   Transcript of earning call: SJSTOCKSHARK 08/10/16 11:49:29 AM
#2164   2 Quarter talk new info: SJSTOCKSHARK 08/10/16 09:11:57 AM
#2163   As I suspected there was no real news SJSTOCKSHARK 08/09/16 08:21:49 PM
#2162   Here is the report on the quarter... BioTech-Rookie 08/09/16 05:16:06 PM
#2161   GP, We may get the details on 8/10/16 SJSTOCKSHARK 08/08/16 10:56:22 PM
#2160   Of course that's too long but they will Gpheart2013 08/08/16 11:50:50 AM
#2159   Did you see the target completion date? Dec. dmoffat 08/08/16 11:08:38 AM
#2158   BIG News. Clinical trials.com shows BPTH is Gpheart2013 08/08/16 10:36:25 AM
#2157   Leaking a little? You are joking, right. It's Gpheart2013 08/04/16 01:46:13 AM
#2156   We are heading North! The tranny is leaking wingshooterr 08/02/16 09:34:39 AM
PostSubject